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140 D. Shahin et al.Methods: In a cross-sectional study, blood samples were drawn from 54 SLE patients, 93 of their
FDRs who consented to enroll into the study and 76UHCs.Measurement of serum IFN-a by amod-
iﬁed ELISA was carried out. Data were analyzed for associations of serum IFN-a levels with autoan-
tibodies titer.
Results: Mean serumIFN-a inFDRswas statistically higher than theUHCs and lower than inSLE
patients (P< 0.0001) and it was correlated with ANA titer (r= 0.6, P< 0.0001) and anti ds DNA
titer (r = 0.62, P< 0.0001).
Conclusion: IFN-a is a crucial player in the complicated autoimmune changes that occur in SLE
and serum IFN-a can be a useful marker identifying persons who are at risk of future disease develop-
ment.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disease characterized by wide spread immunologic abnor-
malities and multiple organ involvement [1]. The precise
pathogenesis of SLE remains unknown, however, genetic fac-
tors in the presence of a permissive environment are involved
[2]. One of the factors suggested to play a role in the pathogenesis
of SLE is interferon-a (IFN-a), a cytokine with both antiviral
and immune-regulatory functions [3], which has been found in
increased levels in SLE patients [4–9]. The potential role of this
cytokine in SLE development is further suggested by the ﬁnding
that SLE patients produce IFN-a in an abated fashion and this
cytokine inducesmonocytes tomature into dendritic cells (DCs)
[10]; a key regulator of antigen presentation.
A causative role for IFN-a in SLE is suggested more
directly by the observation that IFN-a therapy in patients with
nonautoimmune disorders, induced autoantibody production,
including antinuclear antibodies (ANA) and anti double
stranded DNA (ds DNA), and occasionally also a lupus-like
syndrome [11–13] which typically resolved after IFN-a therapy
discontinuation [13,14]. Furthermore, IFN-a administration
frequently lead to other autoimmune disorders such as im-
mune mediated thyroid diseases [15], type I diabetes mellitus
[16], multiple sclerosis and inﬂammatory arthritis [17].
SLE is a familial disease and SLE family members have
higher susceptibility to develop SLE and non-SLE autoimmune
disorders [18,19], and showed more prevalent autoantibodies
than the unrelated healthy population [20–22]. Abnormally
high levels of serum IFN-a were frequently found in healthy
ﬁrst degree relatives (FDRs) of SLE patients [23]. Advances
in genetics, immunology and environmental epidemiology sug-
gest that early or even preclinical identiﬁcation of individuals at
high risk to evolve into lupus may be feasible [20,24,25].
In the current study, we examined serum IFN-a levels and
associated demographic, immunologic and laboratorial fea-
tures in Egyptian SLE patients and their FDRs in comparison
to unrelated healthy controls (UHCs) in order to identify indi-
viduals at the greatest risk for clinical illness.2. Patients and methods
2.1. Study design
In a cross-sectional analysis, SLE patients, who were consecu-
tively seen in, or referred to the Rheumatology and Immunol-
ogy clinics – Mansoura University Hospital and MansouraUniversity Children’s Hospital between September 2009–
2010 were invited to participate if they had at least one sibling
who or their guardians consented to enroll in the study.
The study was approved by the Ethical Committee of
Mansoura School of Medicine and informed consent was
obtained from every study participant or their guardians. All
the clinical data were assessed at the time of blood donation
and all the demographic, clinical, and serological characteris-
tics of the studied subjects were evaluated and recorded by a
rheumatologist.
2.2. Study population
The studied subjects were divided into three categories:
(1) SLE patients: All included lupus patients fulﬁlled the
1997 American College of Rheumatology (ACR) revised
criteria for SLE Classiﬁcation [26]. No more criteria
were required for patients’ enrollment.
(2) First-degree relatives (FDRs): Deﬁned as brothers and
sisters of included SLE patients who or their guardians
provided informed consent. They underwent thorough
clinical examination to screen for autoimmune diseases.
FDRs having at least one but fewer than four of the cri-
teria for SLE were deﬁned as incomplete lupus erythe-
matosus (ILE) [27].
(3) Unrelated healthy controls (UHCs): They were recruited
from medical students, nursing staff, healthy relatives of
non autoimmune disease patients. All the controls were
subjected to a thorough history taking and clinical exam-
ination to ascertain the absence of any personal or family
history of autoimmune disease.
2.3. Exclusion criteria
Individuals with a personal history of malignancy, recent infec-
tion, viral hepatitis or treatment by IFN-a were not eligible for
the present study.
2.4. Laboratorial analysis
From each patient 5 ml venous blood was collected, one
milliliter was withdrawn into plastic tube containing the
dipotassium salt of EDTA at a ﬁnal concentration of
1.2 mg EDTA/ml venous blood which was used for perform-
ing CBC using a cell counter (Sysmex K· 20), 2 ml was
added into a tube containing trisodium citrate for perform-
Table 1 General features of studied population.
SLE patients
(n= 54)
FDRs
(n= 93)
UHCs
(n= 76)
P for
ANOVA*
Scheﬀe post hoc test
P value patients vs.
FDRs
P value FDRs vs.
UHCs
Age/in years (mean ± SD)
Total
participants
21.2 ± 11.1 19.5 ± 9.8 20.9 ± 11.8 ns
Adults 29.5 ± 9.4 28.3 ± 6.1 31.6 ± 8 ns
Pediatrics 12.2 ± 2.9 11.3 ± 3.5 ns
Gender n (%)
Female 44 (81.5%) 63 (67.7%) 48 (63.2%)
Male 10 (18.5%) 30 (32.3%) 28 (36.8%)
Age category n (%)
Adults 28 (51.9%) 45 (48.4%) 36 (47.4%)
Pediatrics 26 (48.1%) 48 (51.6%) 40 (52.6%)
ILE – 18 –
Hb 11.3 ± 1.9 13.3 ± 1.6 13.5 ± 1.6 <0.0001 <0.0001 ns
WBCs 4.6 ± 1.6 4.9 ± 1.1 6 ± .8 <0.0001 <0.0001 ns
Platelet 262.3 ± 107.3 342.6 ± 96.2 374.3 ± 119.9
<0.0001 ns 0.001
ESR 71.6 ± 35.2 14.5 ± 3.6 12.9 ± 2.6 <0.0001 <0.0001 ns
P signiﬁcant <0.05.
ns = non signiﬁcant.
FDRs = ﬁrst degree relatives, ILE = incomplete lupus erythematosus, UHCs = unrelated healthy controls, Hb = hemoglobin,
WBCs = white blood cell count, ESR= erythrocyte sedimentation rate, ANA= antinuclear antibody, dsDNA= double stranded DNA.
* One way ANOVA.
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blood.
Twoml was collected into clean dry plastic tube and allowed
to clot, the yielded serum was used for performing ANA assay
using ANA serum enzyme immune assay kit (BinDazyme, Bir-
mingham, UK), double stranded DNA antibody assay using
enzyme linked immune sorbent assay (ELISA) (Immulisa, Im-
mco Diagnostic, NY, USA) and serum level of IFN-a which
was measured using an enzyme linked immuno sorbent assay
(ELISA) kit (Bender, Medsystems, Vienna, Austria). To neu-
tralize heterotrophile antibodies and avoid false-positive levels
of IFN-a, a modiﬁed protocol described by Aly et al. [28] by
adding 5%mouse serum to the assay buffer was used in the cur-
rent assay.
2.5. Statistical analysis
Data were analyzed using SPSS (version 17). Data were ex-
pressed as mean ± SD and frequencies. Differences between
continuous variables were analyzed by t-test and one way AN-
OVA followed by Tukey’s post hoc test to determine signiﬁ-
cance between groups. Dichotomous variables were analyzed
by 2 and Fisher’s exact test whenever applicable. P values
<0.05 were considered signiﬁcant.
3. Results
3.1. General characteristics of studied population
Demographic features and laboratorial characteristics of the
included participants were given in Tables 1 and 2. The
study population consisted of ﬁfty-four SLE patients,ninety-three FDRs and seventy-six UHCs with mean age
of (by years) 21.2 ± 11.1, 19.5 ± 9.8and 20.9 ± 11.8, respec-
tively. Meanwhile, females represented 81.5% of SLE
patients, 67.7% of FDRs and 63.2% of UHCs, adult popu-
lation consisted of 51.9% of SLE patients, 48.4% of FDRs
and 47.4% of UHCs. Table 1. However, 33.3% of the ILE
(n= 18) subset of FDRs were adults and 66.7% were pedi-
atrics and 52% of the asymptomatic FDRs (n= 75) were
adults and 48% were pediatrics the difference was not statis-
tically signiﬁcant.
The mean hemoglobin levels were comparable in the stud-
ied groups. SLE patients and FDRs had signiﬁcantly lower
WBCs than did the UHCs and only SLE patients showed sig-
niﬁcantly higher ESR and lower platelet count as compared
with FDRs and UHCs. (Table 1).
3.2. Serum INF-a
The mean levels of IFN-a were 65.3 ± 53.4 pg/ml for SLE pa-
tients, 19.5 ± 23 pg/ml for FDRs and 5.2 ± 5.2 pg/ml for
UHCs as shown in Fig. 1. The difference was statistically sig-
niﬁcant by ANOVA (P< 0.0001). Tukey’s post hoc test re-
vealed that the difference between patients and FDRs was
statistically signiﬁcant (P< 0.0001 with a 95% CI 33.6–58)
and the difference between FDRs and UHCs was found to
be statistically signiﬁcant (P= 0.007 with a CI of 3.3–25.4)
(Fig. 1).
Within the subset of FDRs, the mean serum IFN-a in
FDRs with ILE (53.8 ± 31.4 pg/ml) was signiﬁcantly higher
than in asymptomatic FDRs (11.3 ± 8.4 pg/ml) (P< 0.0001)
and the asymptomatic FDRs had a signiﬁcant higher mean
serum IFN-a than UHCs (P< 0.0001). (Table 2).
Table 2 Characteristics of FDRs subsets in comparison to unrelated healthy controls.
UHCs
(n= 76)
FDRs (n= 93) p for
ANOVA
Scheﬀe post
hoc test
Asymptomatic
FDRs (n= 75)
FDRs with ILE
(n= 18)
p1 p2
Age (in years) 20.9 ± 11.8 20.3 ± 10 16.2 ± 8.6 ns –
–
Hb 13.5 ± 1.6 13.6 ± 1.6 12 ± 1.4 <0.0001 ns
<0.0001 WBCs 5.6 ± .8 5.1 ± 1.1 4.3 ± .7 <0.0001
<0.0001 <0.0001
Platelet 374.3 ± 119.9 343.2 ± 104.2 339.8 ± 52.1 0.04
ns ns
ESR 12.9 ± 2.6 13.5 ± 3 18.5 ± 2.8 <0.0001 ns
<0.0001 ANA (mean ± SD) (IU/
ml)
6 ± 4.9 10 ± 6.7 24.2 ± 2.8
<0.0001 <0.0001 <0.0001
Anti ds DNA
(mean ± SD) (IU/ml)
11.2 ± 9.9 17.4 ± 10.3 37.7 ± 6.4 <0.0001 <0.0001
<0.0001 IFN-a (mean ± SD) (pg/
ml)
5.2 ± 5.2 11.3 ± 8.4 53.8 ± 31.4
<0.0001 <0.0001 <0.0001
p Signiﬁcant <0.05.
p1 = p Value for asymptomatic ﬁrst degree relatives vs. unrelated healthy controls.
p2 = p Value for ﬁrst degree relatives with incomplete lupus vs. asymptomatic ﬁrst degree relatives.
ns = non signiﬁcant.
IFN-a= interferon-a, FDRs = ﬁrst degree relatives, ILE = incomplete lupus erythematosus, UHCs = unrelated healthy controls,
Hb = hemoglobin, WBCs = white blood cell count, ESR= erythrocyte sedimentation rate, ANA= antinuclear antibody, ds DNA= double
stranded DNA.
Figure 1 Mean serum INF-alpha levels in SLE patients, their
ﬁrst degree relatives and healthy unrelated controls (ANOVA
P< 0.0001).
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1) Antinuclear antibody (ANA): The overall mean ANA
titer in SLE patients (66.2 ± 26.5 IU/ml) was higher
than in FDRs (12.7 ± 8.3 IU/ml) or the UHCs (6 ±4.9 IU/ml), the difference was signiﬁcant between the
three groups (P< 0.0001) (Fig. 2). Further analysis
was carried out and the difference between patients
and FDRs (P< 0.0001, 95% CI 47.7–59.3), on one side,
and FDRs and UHCs, on the other side, (P= 0.008,
95% CI 1.4–11.9) were statistically signiﬁcant. (Fig. 2).
Similarly FDRs with ILE showed higher mean ANA
titre (24.2 ± 2.8 IU/ml) than in asymptomatic FDRs
(10 ± 6.7 IU/ml) or the UHCs (6 ± 4.9 IU/ml)
(P< 0.0001) (Table 2).
2) Anti ds DNA antibody (ds DNA): Although FDRs in the
current study showed signiﬁcantly lower anti ds DNA
(21.3 ± 12.6 IU/ml) as compared to SLE patients
(107.2 ± 34.2 IU/ml) (P< 0.0001, 95% CI 78–93.8),
they had higher overall mean levels as compared with
UHCs (11.2 ± 9.9) (P= 0.003, 95% CI 3–17.3)
(Fig. 3). Further analysis of FDRs subgroups and
UHCs, a rising anti ds DNA titer was observed; starting
by 11.2 ± 9.9 in UHCs to 17.4 ± 10.3 in asymptomatic
FDRs to 37.7 ± 6.4 in FDRs with ILE. The difference
was statistically signiﬁcant, P< 0.0001 (Table 2).
3.4. Pearson’s correlations between serum IFN-a levels and
participants characteristics
FDRs revealed, On one hand, a signiﬁcant negative correla-
tions between serum IFN-a levels and FDRS age (r= 0.34,
P= 0.001), mean hemoglobin (r= 0.5, P< 0.0001), and
Figure 2 Mean serum ANA titer in SLE patients, their ﬁrst
degree healthy unrelated controls (ANOVA P< 0.0001).
Figure 3 Mean serum anti ds DNA titer in SLE patients, their
ﬁrst degree relatives and healthy unrelated controls (ANOVA
P< 0.0001).
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positively correlated with ESR (r= 0.5, P< 0.0001), ANA ti-
ter (r= 0.6, P< 0.0001), and anti ds DNA (r= 0.62,
P< 0.0001) (Table 3). Furthermore, a nearly similar pattern
of correlations was observed in the total participants (Table 3).
4. Discussion
Detecting autoimmune disease in early or preclinical stages is
clinically important because the institution of treatment prior
to the onset of organ damage has a greater chance to amelio-
rate or even cure the disease [29]. Lately, much insight has
been gained regarding IFN-a as a causal factor for SLE,
and was suggested as a useful tool which can evaluate current
disease activity and identify patients who are at risk of future
disease ﬂares [30]. Even though preclinical identiﬁcation of
individuals at risk of SLE might be feasible [11,20,24,31],
the development of quantitative SLE risk proﬁle is still deﬁ-
cient [24].
Many previous investigators [4–9] observed increased levels
and activity of IFN-a in SLE patients. This was consistent withthe ﬁndings in the present study. More interestingly, FDRs in
the current study had signiﬁcant higher IFN-a than UHCs.
Given that SLE family members share the same genetic back-
ground with their SLE relative patients [19,32] and that serum
IFN-a activity was estimated to have a broad-sense heritability
of 48% in SLE families [23]; FDRs of SLE patients may prob-
ably produce IFN-a in an abated fashion as in SLE patients
[3]. Indeed, SLE blood represented a dendritic cell (a key con-
troller of immunity, tolerance, and IFN-a production) induc-
ing environment [10,33]. It was found that the serum of SLE
patients contains an IFN-a inducing factors that induce the
production of large quantities of IFN-a in normal blood leu-
kocytes in vitro [34,35].
Further investigations of this IFN-a inducing factor in SLE
revealed that immune complexes containing nucleic auto-
antibodies were essential for the induction of expression of
IFN-a [14]. In agreement with these observations, auto-
antibodies titers and serum IFN-a, in the current study, clearly
showed stepwise increase in the studied groups going from
UHCs to asymptomatic FDRs to FDRs with ILE to SLE pa-
tients. Similar ﬁndings were recently reported by Li et al. [24].
They showed that IFN-a genes expression were the speciﬁcities
that most clearly showed stepwise increase in their studied
groups starting by low ANA healthy controls, through high
ANA healthy controls and ending by SLE patients. Data from
earlier studies on auto-antibodies proﬁle of FDRs of SLE pa-
tients [20,36] were in accordance to the data from the present
study, indicating a familial basis to mount an immune
response.
Previous investigators suggested at least three phases in the
development of SLE autoimmunity [37,38]; normal immunity
progresses to benign autoimmunity through the inﬂuence of
genetic composition and environment. Later, benign autoim-
munity progresses to pathogenic autoimmunity. Symptoms
of clinical illness appear soon after pathogenic autoimmunity
develops. Our serologic and clinical ﬁndings along with their
strong association with serum IFN-a levels, in the current
study, further supported a crescendo of autoimmunity culmi-
nating in clinical illness. First, the UHCs in the present study
represented the phase of normal immunity, and the asymptom-
atic FDRs represented the phase of benign autoimmunity.
Finally, the FDRs with ILE, in the present study, symbolized
the third pathogenic autoimmunity phase, that is marked by
the presence of more ominous autoantibodies and inﬂamma-
tory markers.
In-depth reading of the strong association between IFN-a
levels and autoantibodies titer in the current study further indi-
cated an essential role for IFN-a in the development of SLE.
Our results could be explained by the hypothesis formulated
by RO¨nnblom and Alm [3] in which type I IFN system is cru-
cial to the development of SLE in two distinct phases. Initially,
autoantibodies against nucleic acids and associated proteins
are generated during infections (exogenous IFN-a inducers).
In the second phase, immune complexes form and act as
endogenous IFN-a inducers, which sustain the autoimmune
process by prolonging the production of IFN-a. Furthermore,
persistently elevated IFN-a might promote autoantibody class
switch from immunoglobulin (Ig) M to the more pathogenic
IgG class [39]. This proposed mechanism will operate in the
genetically predisposed individuals, such as SLE family mem-
bers, to develop SLE. In accordance to the results of the pres-
ent work, data from previous studies showed a good
Table 3 Pearson’s correlations between serum IFN-a levels and characteristics of study participants, FDRs and asymptomatic FDRs
subset.
INF-a in total participants (n= 223) INF-a in total FDRs (n= 93) INF-a in asymptomatic FDRs (n= 75)
r p r p r p
Age 0.05 ns 0.34 0.001 0.1 ns
Hb 0.5 <0.0001 0.5 <0.0001 0.3 0.02
WBCs 0.36 <0.0001 0.3 0.006 0.05 ns
Platelet 0.3 <0.0001 0.1 ns 0.2 ns
ESR 0.77 <0.0001 0.5 <0.0001 0.6 <0.0001
ANA 0.75 <0.0001 0.6 <0.0001 0.2 0.05
Anti dsDNA 0.77 <0.0001 0.62 <0.0001 0.4 0.001
p signiﬁcant < 0.05.
ns = non signiﬁcant.
IFN-a= interferon-a, FDRs = ﬁrst degree relatives, Hb = hemoglobin, WBCs = white blood cell count, ESR= erythrocyte sedimentation
rate, ANA= antinuclear antibody, ds DNA= double stranded DNA.
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body titer and/or proﬁles in SLE patients [6,8,9,40] and indi-
viduals with ILE [39,41]. On the other hand, Niewold et al.
[23] reported no relation between IFN-a activity and ANA
in their studied healthy family members, and hypothesized that
IFN-a is an independent primary risk factor that might be
familial. This contrast between our results and Niewold’s
may be related to different laboratory methods used for assess-
ment of IFN-a. Niewold et al. [23] developed a functional bio-
assay to measure the ability of patients’ sera to cause IFN
induced gene expression. However, in the current work, a
modiﬁed ELISA, in which 5% mouse serum was added to
the assay buffer to adsorb the heterophile antibodies and im-
prove the speciﬁcity as recommended by Aly et al. [28], was
used for direct estimation of serum IFN-a levels.
The clinical observation that patients with active SLE are
often leucopenic may be related to chemokines [42] and adhe-
sion molecules [43] driving lymphocytes out of the vascular
space and increasing leukocytes adhesion to vessel wall. Bauer
et al. [40,44] demonstrated that up to 12 chemokines were
upregulated in the serum of SLE patients, and most of these
chemokines were inducible by IFN-a. The negative correlation
between WBCs and IFN-a levels observed in the current work
lends further support for this idea. Another possible explana-
tion is that IFN-a, itself, has an inhibitory effect on B cell lym-
phopoiesis in bone marrow [45,46]. The current observed
correlation between IFN-a and clinical laboratory tests such
as elevated ESR, lower leucocytic count, and lower platelet
count was supported by a number of reports in the literature
[6,8,9,41,47].
The ﬁnding that the expression of type I IFN signature was
almost universal in pediatric SLE patients [48] had shed light
on the inverse correlation, found in the current study, between
serum IFN-a and the age of the participants, and explained,
even though not statistically signiﬁcant, the relatively higher
number of the pediatric ILE as compared to the adult ILE.
A similar inverse correlation in female SLE patients and their
healthy female FDRs was also reported [49].
The relatively high percentage of ILE cases among FDRs in
the present study could be explained on the basis that the rela-
tives of patients with lupus became more aware by the disease
than other population and seek medical consultation on suspi-
cion, thus facilitating early diagnosis. Another possible explana-
tion is that siblings who share a common genetic predispositionto SLE tend to reach the threshold for manifestation of SLE
within similar time period during which accumulated environ-
mental factors played a role [50].
This study was limited by the cross-sectional design which
does not enable follow up of longitudinal changes that evolve
over time for further interpretation of the signiﬁcance of IFN-
a in predicting those individuals who evolve into the full clin-
ical lupus.
In conclusion, our results supported that IFN-a is a crucial
player in the complicated autoimmune changes that occur in
SLE, and it can be a useful marker identifying persons who
are at risk of future disease development. Furthermore, down-
regulation of IFN-a could be a therapeutic or possibly even
preventive approach, reducing the overall SLE disease burden
and preventing end organ damage.
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